The Claim

Treatment with GLP-1 receptor agonists, including Exenatide and Dulaglutide, is associated with reductions in body weight, body mass index (BMI), and glycated hemoglobin (HbA1c) levels in human participants, as observed across multiple clinical studies, which aligns with their established metabolic effects.

Source: Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
20score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

People who take certain diabetes drugs like Exenatide or Dulaglutide tend to lose weight and have better blood sugar control, according to several medical studies.

See the scientific wording

Treatment with GLP-1 receptor agonists such as Exenatide and Dulaglutide is associated with reductions in body weight, BMI, and HbA1c in human participants across multiple clinical studies, consistent with their known metabolic effects.

What the research says

1 study

  1. Study: Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.

    The study looked at drugs like Exenatide and Dulaglutide in people and found they helped lower weight, BMI, and blood sugar levels, which matches what the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.